Scilex Holding (SCLX) Cash & Equivalents Growth (5y) (2025 - 2026)
Scilex Holding (SCLX) Cash & Equivalents Growth (5y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,162,528.78 Bn | 93,162,523.82 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.87 Bn | 1,012.58 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 575.51 Bn | 553.46 Bn | 15.96 Bn |
| 4 | AbbVie | 400.43 Bn | 391.08 Bn | 10.78 Bn |
| 5 | Merck | 294.19 Bn | 288.54 Bn | 12.09 Bn |
| 6 | Amgen | 182.41 Bn | 170.37 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 150.97 Bn | 143.24 Bn | 5.52 Bn |
| 8 | Pfizer | 145.75 Bn | 132.97 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.35 Bn | 102.90 Bn | 8.07 Bn |
| 10 | Scilex Holding | 57.99 Mn | -91.94 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240.85% |
| Dec 31, 2025 | 176.77% |
| Sep 30, 2025 | 62.73% |